News & Updates

Show Multimedia Only

Dietary modification ups glaucoma risk in women

04 Jun 2023

Dietary modification (DM) among individuals in the lowest quartile for percentage calories from total fat at baseline is associated with a higher risk of incident primary open-angle glaucoma (POAG) among women, irrespective of age or race, suggests a recent study.

Dietary modification ups glaucoma risk in women

04 Jun 2023

Original New Drug Application Approvals by US FDA (16-31 May 2023)

01 Jun 2023

New drug applications approved by US FDA as of 16-31 May 2023 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (16-31 May 2023)

01 Jun 2023

Serum ADMA levels linked to circadian BP variability in glaucoma

27 May 2023

Serum levels of asymmetric dimethylarginine (ADMA) seem to play a major role in the disturbance of circadian blood pressure (BP) variability in patients with glaucoma, suggests a recent study.

Serum ADMA levels linked to circadian BP variability in glaucoma

27 May 2023

AI raises the bar for diagnosing severe TED

23 May 2023 by

Artificial intelligence (AI) can help diagnose thyroid eye disease (TED) and assess for severity by analysing CT scans, reports an expert at ARVO 2023.

AI raises the bar for diagnosing severe TED

23 May 2023

3-week azithromycin on par with 6-week doxycycline for treating MGD

22 May 2023

In the treatment of moderate-to-severe meibomian gland dysfunction (MGD), a 3-week course of oral azithromycin leads to outcomes that are similar to that achieved with a 6-week course of oral doxycycline, according to a study.

3-week azithromycin on par with 6-week doxycycline for treating MGD

22 May 2023

Delayed capsulotomy much preferable over early procedure to prevent AEs

18 May 2023

Ocular hypertension (OHT) and macular edema (ME) are the most common and relevant adverse events (AEs) following neodymium:yttrium-aluminum-garnet posterior capsulotomy (Nd:YAG-caps), reports a study. These AEs normally occur within 3 months after the procedure, which stresses the need for a close follow-up during this period or a delayed capsulotomy.

Delayed capsulotomy much preferable over early procedure to prevent AEs

18 May 2023

Original New Drug Application Approvals by US FDA (01-15 May 2023)

16 May 2023

New drug applications approved by US FDA as of 01-15 May 2023 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (01-15 May 2023)

16 May 2023

Switching to brolucizumab improves visual acuity in nAMD

11 May 2023 by

Switching from other anti-VEGF* agents to brolucizumab only helps improve visual acuity and reduces disease activity in patients with neovascular (wet) age-related macular degeneration (nAMD)

Switching to brolucizumab improves visual acuity in nAMD

11 May 2023

Delaying treatment of glaucoma not necessarily harmful

10 May 2023

Withholding treatment in individuals with glaucoma does not appear to lead to serious consequences in terms of visual function, according to a study.

Delaying treatment of glaucoma not necessarily harmful

10 May 2023

Using visual acuity to guide diabetic macular oedema treatment

04 May 2023 by

Diabetic macular oedema (DME) patients with visual acuity (VA) of 20/50 or worse are likely to experience superior clinically relevant VA outcomes at 1 year and over 2 years using aflibercept vs bevacizumab or ranibizumab, according to an analysis of Diabetic Retinopathy Clinical Research (DRCR) Network’s Protocol T data presented at the 38^th Asia-Pacific Academy of Ophthalmology (APAO 2023) Congress.

Using visual acuity to guide diabetic macular oedema treatment

04 May 2023

News & Updates

Filter by Specialty:

Specialty:

Dietary modification ups glaucoma risk in women

Dietary modification ups glaucoma risk in women

Original New Drug Application Approvals by US FDA (16-31 May 2023)

Original New Drug Application Approvals by US FDA (16-31 May 2023)

Serum ADMA levels linked to circadian BP variability in glaucoma

Serum ADMA levels linked to circadian BP variability in glaucoma

AI raises the bar for diagnosing severe TED

AI raises the bar for diagnosing severe TED

3-week azithromycin on par with 6-week doxycycline for treating MGD

3-week azithromycin on par with 6-week doxycycline for treating MGD

Delayed capsulotomy much preferable over early procedure to prevent AEs

Delayed capsulotomy much preferable over early procedure to prevent AEs

Original New Drug Application Approvals by US FDA (01-15 May 2023)

Original New Drug Application Approvals by US FDA (01-15 May 2023)

Switching to brolucizumab improves visual acuity in nAMD

Switching to brolucizumab improves visual acuity in nAMD

Delaying treatment of glaucoma not necessarily harmful

Delaying treatment of glaucoma not necessarily harmful

Using visual acuity to guide diabetic macular oedema treatment

Using visual acuity to guide diabetic macular oedema treatment